Skip to main content
SpringerLink
Log in
Book cover

Reducing Drug Attrition pp 139–158Cite as

Reducing Drug Attrition: Safety Pharmacology

  • Chapter
  • First Online:

  • 753 Accesses

Part of the book series: Topics in Medicinal Chemistry ((TMC,volume 11))

Abstract

Safety pharmacology studies have been used to support drug discovery and development programs by many sponsors for decades. The objectives of these studies are to identify and characterize pharmacology activities of drug candidates that can contribute to adverse effects and safety of clinical trial participants and patients. International guidelines for safety pharmacology were adopted in 2001 and 2005, and results from these studies are now a component of almost all regulatory submissions. By insuring the quality of the data from these studies and effectively communication results in terms of a risk assessment, the safety pharmacology package can be used to identify drug candidates with lower risk for attrition and to mitigate or better manage safety risks during clinical development.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711

    Google Scholar 

  2. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL (2010) How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 9:203

    Google Scholar 

  3. Pammolli F, Magazzini L, Riccaboni M (2011) The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 10:428

    Google Scholar 

  4. Mahajan R, Gupta K (2010) Food and drug administration’s critical path initiative and innovations in drug development paradigm: challenges, progress, and controversies. J Pharm Bioallied Sci 2:307

    Google Scholar 

  5. Zbinden G (1979) Pharmacological methods in toxicology. Pergamon, Elmsford

    Google Scholar 

  6. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN (2001) The QT interval. Prog Cardiovasc Dis 43:1

    Google Scholar 

  7. Koerner JE, Siegl PKS (2013) Safety pharmacology: guidelines S7A and S7B. In: van der Laan JW, DeGeorge JJ (eds) Global approach in safety testing, aaps advances in the pharmaceutical sciences series, vol 5. Springer, p 243

    Google Scholar 

  8. Whitebread S, Hamon J, Bojanic D, Urban L (2005) Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov Today 10:1421

    Google Scholar 

  9. Bowes J, Brown AJ, Hamon J, Jarolimek W, Sridhar A, Waldron G, Whitebread S (2012) Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nature Reviews Drug Discovery 11:909

    Google Scholar 

  10. Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey A-M, Ehrhart J et al (2008) Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 154:1465

    Google Scholar 

  11. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M et al (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109

    Google Scholar 

  12. Bass AS, Siegl PK, Gintant GA, Murphy D, Porsolt R (2008) In Gad SC (ed) Preclinical development handbook: toxicology. Wiley, Chicester, Chap. 18, p 611

    Google Scholar 

  13. Gad SC (2012) Safety pharmacology in pharmaceutical development: approval and post-marketing surveillance. CRC, Boca Raton

    Google Scholar 

  14. Cavero I (2007) Using pharmacokinetic/pharmacodynamic modelling in safety pharmacology to better define safety margins: a regional workshop of the Safety Pharmacology Society. Expert Opin Drug Saf 6:465

    Google Scholar 

  15. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PKS, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58:32

    Google Scholar 

  16. Smith DA, Di L, Kerns EH (2010) The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov 9:929

    Google Scholar 

  17. Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc BA, Perkins DG, Shipley LA (2002) Drug metabolites in safety testing. Toxicol Appl Pharmacol 182(3):188–196

    Google Scholar 

  18. Hastings KL, El-Hage J, Jacobs A, Leighton J, Morse D, Osterberg R (2003) Drug metabolites in safety testing. Toxicol Appl Pharmacol 190(1):91–92

    Google Scholar 

  19. FDA Guidance (2008) Safety testing of drug metabolites. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079266.pdf

  20. Cavero I (2013) 2012 Annual Meeting of the Safety Pharmacology Society: spotlight on targeted oncology medicines. Expert Opin Drug Saf 12:589–603

    Google Scholar 

  21. Pugsley MK, Curtis MJ (2012) Methodological innovations expand the safety pharmacology horizon. J Pharmacol Toxicol Methods 66(2):59–62

    Google Scholar 

  22. Guth BD, Bass AS, Briscoe RJ, Chivers S, Siegl P, Valentin J-P (2009) Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicological studies. J Pharmacol Toxicol Methods 60:107

    Google Scholar 

  23. Redfern WS, Ewart LC, Lainée P, Pinches M, Robinson S, Valentin J-P (2013) Functional assessments in repeat-dose toxicity studies: the art of the possible. Toxicol Res http://pubs.rsc.org/en/content/articlelanding/2013/tx/c3tx20093k

  24. Jonsson MK, Vos MA, Mirams GR, Duker G, Sartipy P, de Boer TP, van Veen TA (2012) Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG. J Mol Cell Cardiol 52:998

    Google Scholar 

  25. Trepakova ES, Koerner J, Pettit SD, Valentin JP; HESI Pro-Arrhythmia Committee (2009) A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays. J Pharmacol Toxicol Methods 60:45

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Siegl Pharma Consulting LLC, Blue Bell, PA, USA

    Peter Siegl

Authors
  1. Peter Siegl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Siegl .

Editor information

Editors and Affiliations

  1. Vertex Pharmaceuticals, Boston, Massachusetts, USA

    James R. Empfield

  2. Vertex Pharmaceuticals, Boston, Massachusetts, USA

    Michael P Clark

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Siegl, P. (2013). Reducing Drug Attrition: Safety Pharmacology. In: Empfield, J., P Clark, M. (eds) Reducing Drug Attrition. Topics in Medicinal Chemistry, vol 11. Springer, Berlin, Heidelberg. https://doi.org/10.1007/7355_2013_26

Download citation

Publish with us

Policies and ethics

Search

Navigation